LL

Libette Luce

VP of Regulatory Affairs at Akero

Libette Luce is Vice President of Regulatory Affairs at Akero. She brings over 20 years of experience in the pharmaceutical industry with more than 15 years specializing in global regulatory affairs across multiple therapeutic areas including cardiovascular, dermatology, GI, metabolic and ophthalmic/retinal disease. Libette joins us from Innocoll Biotherapeutics, where she was VP, Head of Regulatory Affairs leading development and commercial global regulatory initiatives for the company’s product portfolio in the non-opioid pain management space. Prior to Innocoll, she was Executive Director of Global Regulatory Affairs at Bausch Health Companies, Inc. leading the management of product portfolios for Bausch’s business units, GI (Salix Pharmaceuticals), dermatology (Dow Pharmaceuticals) and ophthalmology (Bausch and Lomb, Inc.). She has also held global regulatory positions at Allergan (Abbvie), Forest Laboratories (Abbvie), Roche, and Schering-Plough (Merck). Libette holds a Master of Arts in Diplomacy and International Relations from Seton Hall University and a Bachelor of Arts in Political Science and International Studies from the University of Miami.

Location

Branchburg Township, United States

Links

Previous companies


Org chart

No direct reports

Teams

This person is not in any teams


Offices

This person is not in any offices


Akero

1 followers

Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, efruxifermin (EFX), an engineered Fc-FGF21 fusion protein, is currently being evaluated in a Phase 2b clinical trial as a potential treatment for NASH.